That very week, however, the world of science celebrated an “enormous breakthrough”: the discovery of a new drug based on malaria proteins that can dramatically reduce hard-to-treat bladder cancers.
“It is nowhere. A brand new beam of trust within the business of most cancers. ‘Nivolumab’ for competitive Hodgkin’s lymphoma.
Distribute the term ” ‘Actor. Singer. Ever since she joined a clinical Celixir IPO trial for an experimental drug in Los Angeles, USA, the southern beauty has been upbeat. “It is doing work for me,” she informs her fans. “courageous lady,” “really like u,” “jaldi Aaja,” they respond.
TIME OF BREAKTHROUGHS
It is the best of times, it is the worst of times, on the cancer front. Scientists continue to be baffled by the complexity and smartness of cancer cells: that they find ways to dodge even the most potent therapies, that most cancers’ encompasses not one but hundreds of distinct diseases, that each cancer behaves differently, that two people with the same tumor, at the same stage, receiving the same treatment, can experience radically different outcomes. As a US-based oncologist and Pulitzer-winning writer, Dr. Siddhartha Mukherjee says, “All cancers are equally. However, they’re equally in an exceptional manner” With all that, and cancer is catching up with heart disease as the leading cause of deaths globally, reports the World Health Organization. In India, the latest study based on the National Cancer Registry shows that there are 1.45 million new cases every year, a prevalence of over 3 million at any point in time, over 680,000 deaths a year. Although early detection saves lives, just 12.5 percent of Indians call on a doctor in the early stages.
But it’s also a time of extraordinary breakthroughs and innovations. No, there is no single death-defying magic bullet, but new generations of life-saving and life-extending ‘smart drugs’ are currently being developed and tested. At the root of all, this is the idea that the cure for cancer is inside the patient. And the mantra in labs around the world is precision medication’. That is a line of treatment that is personalized to a patient’s genetic make-up or molecular changes within one’s tumor. Up until now, therapies have all been geared to treat cancer based on where it is located, say, in the breast, bladder, or lung. Now, the shift is increasingly evident in finding precision medicine targeted at genetic glitches. On May 23, in a first, a cancer drug has won approval from the US Food and Drug Administration (USFDA) that can be given to anyone who harbors specific genetic abnormalities found in as many as 15 different types of cancers, all in patients for whom traditional treatment, like chemotherapy, has failed.
There has not been so much excitement as there is now since 2001, when one of the first cancer therapies to show the potential for targeted action, Imatinib, was approved. Thousands of clinical trials are humming with promising drug pipelines, many of which are being used by doctors to benefit patients. “It is a thrilling moment,” says Dr. Anil Suri, director of the National Institute of Immunology in Delhi and the man who discovered SPAG9, the cancer antigen to be used in India’s first anti-cancer vaccine, now under phase II clinical trial in cervical cancer patients. “Most Cancers
Research is at the tipping point of the main discoveries. Innovations in molecular analysis, next-generation gene sequencing, data that is big, and advanced diagnostics are checking an entirely new universe of chances.”